Roll up, roll up, come and get your CBD… toothpaste?
In 2019 it is becoming almost impossible to avoid the barrage of CBD-infused products lining shops along the high street.
Impression Healthcare is taking the CBD industry to its next logical conclusion: infusing CBD into our oral hygiene routine.
Impression has announced it is launching the “world’s first” clinical trial for CBD as a treatment for gingivitis and periodontitis (gum disease).
Forty participants for the trial will be recruited in August for a phase 2a randomised controlled clinical trial, which will evaluate the efficacy and safety of Impression’s CBD-infused toothpaste and mouthwash for patients shuddering from mouth and gum diseases.
Participants will use both the mouthwash and toothpaste three times a day for 30 days, with researchers monitoring their overall gum health, particularly looking for a rise/decrease in gum inflammation.
AXIM Biotechnologies, a US-based pharmaceutical company, will provide Impression with manufactured CBD for the trial.
Impression’s chief executive officer, Joel Latham, expressed his excitement at the announcement of the trial:
“Formal registration of the gingivitis and periodontitis trial represents significant progress in Impression’s medicinal cannabis activities and is the culmination of many months of work by our team and research partners.
“We are excited to have assembled highly qualified researchers for a world first trial for the use of CBD in the treatment of gingivitis and gum disease, which are major problems representing a major market.
“The trials and subsequent commercial sales represent an exciting new potential avenue for the company to generate sales in one of the fastest growing emerging sectors in the world.”
According to Impression, about 20% of the Australian population suffers from moderate to severe gum disease – equating to 5 million people, rising to 40% in the over-55 demographic.
If the trials are successful, we could soon be seeing CBD-infused oral hygiene products in the UK.